Jenna Haaf
Family · Aliquippa, PANPI 1053945824
Payments from drug & device makers
Across 139 payments — averaging $16.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Collegium Pharmaceutical, Inc.$738
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$486
- Valinor Pharma, LLC$159
- Protega Pharmaceutials Inc$141
- Averitas Pharma Inc.$90
- AbbVie$87
- plus $528 from 10 others
What the payments were for
- Food & beverage$2,18098%
- Education$492%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 50 | $738 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 36 | $486 |
| Valinor Pharma, LLC | 15 | $159 |
| Protega Pharmaceutials Inc | 9 | $141 |
| Averitas Pharma Inc. | 4 | $90 |
| AbbVie | 4 | $87 |
| Medtronic | 1 | $86 |
| Teva Pharmaceuticals USA, Inc. | 1 | $81 |
| Vertex | 3 | $73 |
| Scilex Pharmaceuticals Inc. | 4 | $67 |
| Hikma Pharmaceuticals USA | 3 | $62 |
| Impel Pharmaceuticals LLC | 3 | $51 |
| Appliedvr Inc | 2 | $37 |
| Impel Pharmaceuticals Inc. | 2 | $28 |
| Boston Scientific | 1 | $23 |
| Tonix Medicines, Inc. | 1 | $21 |
How this compares
$2,229 in reported general payments places this provider in the 85th percentile of 4,717 family providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 148 | $103,665 |
| OxycontinOxycodone Hcl | 75 | $41,079 |
| MovantikNaloxegol Oxalate | 80 | $35,905 |
| RelistorMethylnaltrexone Bromide | 14 | $31,542 |
| BelbucaBuprenorphine Hcl | 31 | $25,757 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 952 | $17,148 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 723 | $13,909 |
| SymproicNaldemedine Tosylate | 23 | $9,972 |
| Buprenorphine | 41 | $8,820 |
| LinzessLinaclotide | 12 | $6,319 |
| Butorphanol Tartrate | 15 | $5,716 |
| Oxycodone Hcl | 376 | $5,437 |
| Morphine Sulfate ErMorphine Sulfate | 295 | $5,308 |
| Gabapentin | 346 | $4,793 |
| Pregabalin | 177 | $4,189 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca | $738 | $129,422179 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $486 | $31,54214 claims |
| Hikma Pharmaceuticals USABuprenorphine | $62 | $8,82041 claims |
| AbbVieLinzess | $87 | $6,31912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,717 family providers in Pennsylvania.
Other family in Aliquippa
- Kathleen ScholzPittsburgh$397K
- Shannon FitzgeraldAllison Park$370K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Jessica LindenbergerPittsburgh$131K
- Kami NestlerWilkes Barre$129K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
- Amanda GrippoDickson Cty$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.